Abby Hardy, Author at BioTuesdays

Developments

Precipio inks second development pact with H3 Biomedicine

Precipio (NASDAQ:PRPO) and closely-held H3 Biomedicine began a second development project to create a targeted gene panel that H3 will use in its ongoing clinical programs.

June 25, 2019

Feature

Chardan president, Jonas Grossman, talks SPACs

By Abby Hardy As president of Chardan, an independent, global investment bank specializing in healthcare, disruptive technologies, and special purpose acquisition companies (SPACs), Jonas Grossman takes a worldwide view...

June 25, 2019

Executive Moves

Arcus Biosciences names Eric Hoefer as chief commercial officer

Arcus Biosciences (NYSE:RCUS) appointed Eric Hoefer as its chief commercial officer to oversee the company’s global commercial strategy and operations.

June 24, 2019

Developments

Zenabis outperforms design capacity by 35% in May; announces 70% increase in licensed annual cultivation capacity

Zenabis Global (TSX:ZENA) generated cultivation output in May of 908 kg of dried cannabis, which represents a 35.1% outperformance relative to design capacity.

June 24, 2019

Developments

ContraVir Pharma gets positive FDA response to CRV431 pre-IND package for NASH

ContraVir Pharmaceuticals (NASDAQ:CTRV) reported that the FDA provided positive feedback to the company’s pre-IND meeting regarding CRV431 for the treatment of non-alcoholic steatohepatitis (NASH).

June 20, 2019

Markets

BTIG cuts Verastem to Neutral; PT removed

BTIF downgraded Verastem (NASDAQ:VSTM) to “neutral” from “buy” and removed its previous price target of $8 after the company announced that president and CEO, Robert Forrester, was stepping down. The stock closed at $1...

June 20, 2019

Developments

Adamas Pharma reports new data from Phase 3 Parkinson’s disease trial

Adamas Pharmaceuticals (NASDAQ:ADMS) reported retrospective data from pooled Phase 3 trials of GOCOVRI in Parkinson’s disease (PD) patients.

June 19, 2019

Developments

Xeris Pharma reports additional Phase 3 data for ready-to-use glucagon

Xeris Pharmaceuticals (NASDAQ:XERS) reported positive additional results from its global Phase 3 trial of ready-to-use (RTU) liquid glucagon.

June 18, 2019

Developments

PhaseBio Pharma reports positive initial Phase 2a results for antiplatelet reversal drug

PhaseBio Pharmaceuticals (NASDAQ:PHAS) reported initial results from its Phase 2a trial assessing PB2452’s ability to reverse the effects of the antiplatelet drug, ticagrelor, in subjects 50-to-80 years of age.

June 18, 2019

Developments

Lutronic Vision’s R:GEN laser treats first CSC patient at Seoul National University Hospital

Closely-held Lutronic Vision’s R:GEN laser has treated its first central serous chorioretinopathy (CSC) patient at Seoul National University Hospital (SNUH).

June 18, 2019

Author - Abby Hardy

Precipio inks second development pact with H3 Biomedicine

Chardan president, Jonas Grossman, talks SPACs

Arcus Biosciences names Eric Hoefer as chief commercial officer

Zenabis outperforms design capacity by 35% in May; announces 70% increase in licensed annual cultivation capacity

ContraVir Pharma gets positive FDA response to CRV431 pre-IND package for NASH

BTIG cuts Verastem to Neutral; PT removed

Adamas Pharma reports new data from Phase 3 Parkinson’s disease trial

Xeris Pharma reports additional Phase 3 data for ready-to-use glucagon

PhaseBio Pharma reports positive initial Phase 2a results for antiplatelet reversal drug

Lutronic Vision’s R:GEN laser treats first CSC patient at Seoul National University Hospital

Subscribe